Inovio Investors Urged to Join Securities Fraud Lawsuit

The Schall Law Firm Reminds Investors of Opportunity to Lead Case Against Inovio Pharmaceuticals

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO) for alleged violations of federal securities laws. The lawsuit covers a class period from October 10, 2023 to December 26, 2025, and the firm is encouraging investors who purchased the company's securities during that time to contact them about potentially leading the case.

Why it matters

Inovio is a biotechnology company focused on developing DNA medicines to treat and prevent infectious diseases, cancer, and other diseases. The lawsuit alleges the company made false and misleading statements to the market regarding manufacturing issues with its CELLECTRA device and the likelihood of filing a Biologics License Application (BLA) for its INO-3107 drug on time.

The details

According to the complaint, Inovio suffered from manufacturing deficiencies for its CELLECTRA device, which is used to deliver the company's DNA medicines. The lawsuit also claims the company was unlikely to file the INO-3107 BLA by the second half of 2024 as previously stated, and failed to produce sufficient evidence supporting an FDA priority review or accelerated approval for the BLA. The Schall Law Firm alleges these issues rendered Inovio's public statements during the class period false and misleading, ultimately leading to investor losses when the truth came to light.

  • The class period covers October 10, 2023 to December 26, 2025.
  • Investors have until April 7, 2026 to contact the Schall Law Firm to potentially lead the case.

The players

Inovio Pharmaceuticals, Inc.

A biotechnology company focused on developing DNA medicines to treat and prevent infectious diseases, cancer, and other diseases.

The Schall Law Firm

A national shareholder rights litigation firm that is representing investors in the class action lawsuit against Inovio.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”

— Brian Schall, Attorney, Schall Law Firm (Business Wire)

What’s next

The judge will decide on whether to certify the class by April 7, 2026, after which point investors will be represented by an attorney if they choose to join the case.

The takeaway

This lawsuit highlights the importance of transparency and accurate disclosures by publicly traded companies. Investors in Inovio will be closely watching the progress of this case, which could have significant implications for the biotechnology firm if the allegations of securities fraud are proven true.